Conference Coverage

Universal BRCA testing worthwhile for relatives of high-grade serous ovarian cancer patients


 

REPORTING FROM ACOG 2018


“Any opportunity to prevent ovarian cancer is worthwhile,” Dr. Kwon commented. “If an ovarian cancer patient cannot be tested because she declines testing or, more commonly, because she is deceased, her first-degree relative should have BRCA mutation testing, regardless of other personal or family history or ethnicity.”

She and her coinvestigators reported no relevant financial disclosures.

Pages

Recommended Reading

Combined PARP, checkpoint inhibitor regimens show ovarian cancer activity
MDedge Hematology and Oncology
Study: No increased risk of serious AEs with combined urogyn/gyn onc surgery
MDedge Hematology and Oncology
VIDEO: Cervical cancer laparotomy outperforms minimally invasive surgery
MDedge Hematology and Oncology
VIDEO: Interventions target opioid overprescribing after gynecologic surgery
MDedge Hematology and Oncology
Residual single-site ovarian cancer surpasses multisite outcomes
MDedge Hematology and Oncology
Trastuzumab plus chemo shows efficacy for high HER2 endometrial cancer
MDedge Hematology and Oncology
VIDEO: Indocyanine green finds more sentinel lymph nodes
MDedge Hematology and Oncology
Disproportionately low U.S. research funding targets gynecologic cancers
MDedge Hematology and Oncology
What is HIPEC?
MDedge Hematology and Oncology
Leg lymphedema after gynecologic lymphadenectomy exceeds expectations
MDedge Hematology and Oncology